Literature DB >> 31548292

Esketamine for treatment resistant depression.

Sameer Jauhar1, Paul Morrison2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31548292     DOI: 10.1136/bmj.l5572

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions.

Authors:  Leah Vines; Diana Sotelo; Allison Johnson; Evan Dennis; Peter Manza; Nora D Volkow; Gene-Jack Wang
Journal:  Intell Med       Date:  2022-03-07

2.  Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials.

Authors:  Michael P Hengartner; Janus C Jakobsen; Anders Sørensen; Martin Plöderl
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

3.  Ketamine treatment for depression: qualitative study exploring patient views.

Authors:  Sagar Jilka; Clarissa Mary Odoi; Emma Wilson; Sazan Meran; Sara Simblett; Til Wykes
Journal:  BJPsych Open       Date:  2021-01-11

4.  How to deprescribe esketamine in resistant depression? A point of view after first clinical uses.

Authors:  T Taillefer de Laportalière; A Yrondi; A Jullien; P Cestac; F Montastruc
Journal:  Epidemiol Psychiatr Sci       Date:  2022-01-11       Impact factor: 6.892

5.  Mind-Brain Dualism in Psychiatry: Ethical Implications.

Authors:  Walter Glannon
Journal:  Front Psychiatry       Date:  2020-03-03       Impact factor: 4.157

Review 6.  Treatment resistance in psychiatry: state of the art and new directions.

Authors:  Oliver D Howes; Michael E Thase; Toby Pillinger
Journal:  Mol Psychiatry       Date:  2021-07-13       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.